Rainmed Medical Limited (HK:2297) has released an update.
Rainmed Medical Limited has announced the allocation of its HK$78.6 million net proceeds from its Global Offering, detailing the investment in research and development, clinical studies, and commercialization of its Core Products, as well as funding for other pipeline products and general corporate purposes. The supplemental information confirms that the majority of the funds were utilized as intended by the end of 2023, with no changes to the previously published 2023 Annual Report.
For further insights into HK:2297 stock, check out TipRanks’ Stock Analysis page.
